Please login to the form below

Not currently logged in
Email:
Password:

Vaccine development

This page shows the latest Vaccine development news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $425m flu vaccine deal with Germany’s BioNTech

Pfizer signs $425m flu vaccine deal with Germany’s BioNTech

Pfizer signs $425m flu vaccine deal with Germany’ s BioNTech. Pharma giant will take on development and commercial responsibility for candidates. ... Using mRNA is an attractive proposition for flu vaccine development because its can be sued to code

Latest news

More from news
Approximately 0 fully matching, plus 122 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    Feminists pointed to the gendered nature of the vaccine, raising questions as to why only women appeared to have been considered in vaccine development, much like they have historically been in ... While the vaccine remained freely available, it was not

  • Deal Watch September 2016 Deal Watch September 2016

    up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to $125m] and Sanofi ($43.2m). ... In a similar vein Sanofi will receive $43.2m in funding for the mid stage

  • Deal Watch December 2015 Deal Watch December 2015

    409. Kyorin (JP). BMS. Collaboration, licence. Discovery, development and commercialisation of FPR 2 agonists for undisclosed indication. ... 200. Bavarian Nordic (DK). Janssen. Collaboration, licence. Vaccine platform technology for development of

  • Pharma deals during January 2013 Pharma deals during January 2013

    This deal is for technology development and carries a $5m non-refundable payment. ... GSK. JV. Combination paediatrics vaccines. Terminations. Although the active development for Cytos'NIC 002 therapeutic vaccine for smoking cessation had ceased some

  • Pharma deals during October 2012 Pharma deals during October 2012

    The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... LigoCyte has a number of vaccine products in development, including its lead candidate, which is in phase I/II vaccine to prevent norovirus

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • McCann Health appoints Daniel Carucci as global medical director McCann Health appoints Daniel Carucci as global medical director

    Dr Carucci has over 25 years of experience in large-scale innovation programs, vaccine development, organisational leadership, and global public health, during which time he served as VP for global health

  • Sanofi names CSO Gary Nabel to Ebola role Sanofi names CSO Gary Nabel to Ebola role

    Elias Zerhouni, president of Sanofi global research and development, said: “ Given his past experience in public health epidemics as director of the NIH vaccine research centre and his leadership in developing ... He is working with other organisations,

  • Takeda appoints head of vaccines development Takeda appoints head of vaccines development

    Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza. ... development organisation and advanced vaccine development against illnesses

  • Sanofi appoints NIH’s Gary Nabel as chief scientific officer Sanofi appoints NIH’s Gary Nabel as chief scientific officer

    Sanofi appoints NIH’ s Gary Nabel as chief scientific officer. He previously headed vaccine research centre of the US National Institute of Allergy and Infectious Diseases. ... During this period, he provided overall direction of the VRC, including the

  • Peter Chambre joins cancer vaccine biotech Immatics Peter Chambre joins cancer vaccine biotech Immatics

    Peter Chambre joins cancer vaccine biotech Immatics. He replaces Thomas Widmann as chair of the board. ... With IMA901, Immatics' lead multi-peptide based vaccine now in phase III development for renal cancer, and a number of other projects in clinical

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics